<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01066065</url>
  </required_header>
  <id_info>
    <org_study_id>HCIII0110</org_study_id>
    <nct_id>NCT01066065</nct_id>
  </id_info>
  <brief_title>Metabolic Safety of Raltegravir Versus Darunavir in HIV Naive Patients</brief_title>
  <official_title>Metabolic Profile and Cardiovascular Biomarker Pattern Compared in naíve Patients Initiating HAART With TDF-FTC and Raltegravir 400mg BID Vs Darunavir 800 mg Plus Ritonavir 100 mg QD; a One Year Follow-up Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Carlos III, Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Carlos III, Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The advent of new antiretroviral drugs improved the management of HIV naive patients in terms
      of efficacy. However, the long term metabolic profile of this drugs has not yet been compared
      and associations between new antiretrovirals and cardiovascular events remains controversial.

      Moreover, the better tolerability and easy dosage of this new drugs might hypothetically
      influence adherence and QOL of HIV patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>lipid profile defined as a clinically significant increment (delta) in Total cholesterol LDL, HDL y non-LDL cholesterol.</measure>
    <time_frame>baseline and week 12, 24, 36 and 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin resistance defined by HOMA index.</measure>
    <time_frame>baseline and week 12, 24, 36 and 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular biomarkers: ICAM, VICAM, IL-6, PCR hs...</measure>
    <time_frame>baseline and week 12, 24, 36 and 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antiretroviral adherence and quality of life items.</measure>
    <time_frame>baseline and week 12,24,36,48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy defined as viral suppression and CD4 count recovery</measure>
    <time_frame>baseline and week 12,24,36,48</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Raltegravir Cohort</arm_group_label>
    <description>Patients taking RAL 400 mg BID with Truvada</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Darunavir Cohort</arm_group_label>
    <description>Patients taking Darunavir 800 mg QD plus Norvir 100 mg QD with truvada</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive naïve patients regularly attended at a referral outclinic. 1:1 Randomization in
        two arms by a local electronic process.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  VIH-1

        Exclusion Criteria:

          -  pregnancy

          -  previous Antiretroviral exposure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jose Medrano, MD</last_name>
    <phone>+34914532531</phone>
    <email>josemedranolaporte@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Carlos III</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2010</study_first_submitted>
  <study_first_submitted_qc>February 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2010</study_first_posted>
  <last_update_submitted>June 24, 2010</last_update_submitted>
  <last_update_submitted_qc>June 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hospital Carlos III</name_title>
    <organization>Vicente Soriano</organization>
  </responsible_party>
  <keyword>cardiovascular disease</keyword>
  <keyword>HIV</keyword>
  <keyword>metabolic disorder</keyword>
  <keyword>HIV naive patients initiating HAART with Raltegravir or boosted Darunavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

